Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?

J Clin Oncol. 2005 Feb 1;23(4):921-2; author reply 922. doi: 10.1200/JCO.2005.05.700.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / chemistry
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • ErbB Receptors / analysis*
  • Female
  • Gefitinib
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / chemistry
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Quinazolines / therapeutic use*
  • Receptor, ErbB-2 / analysis*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • ErbB Receptors
  • Receptor, ErbB-2
  • Gefitinib